NYSE · FMS
Fresenius Medical Care AG financials
$22.27−2.96%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23.03B | $20.12B | $21.51B | $20.81B | $20.68B | $20.95B | $19.69B | $19.51B | $20.07B | $17.74B |
| Gross profit | $5.90B | $4.95B | $5.44B | $5.25B | $5.60B | $6.49B | $6.08B | $6.08B | $6.79B | $6.01B |
| Gross margin | 25.6% | 24.6% | 25.3% | 25.2% | 27.1% | 31.0% | 30.9% | 31.2% | 33.8% | 33.9% |
| Operating income | $1.31B | $517.6M | $809.6M | $1.60B | $2.07B | $2.59B | $2.47B | $2.54B | $2.56B | $2.50B |
| Net income | $1.15B | $559.7M | $551.6M | $722.3M | $1.14B | $1.37B | $1.35B | $2.34B | $1.44B | $1.22B |
| Net margin | 5.0% | 2.8% | 2.6% | 3.5% | 5.5% | 6.5% | 6.9% | 12.0% | 7.2% | 6.9% |
| Diluted EPS | $3.94 | $1.90 | $1.88 | $2.47 | $3.89 | $4.64 | $4.46 | $7.60 | $4.70 | $3.99 |
| EBITDA | $3.07B | $2.33B | $2.75B | $3.58B | $3.97B | $4.69B | $4.27B | $3.47B | $3.39B | $3.25B |
| Operating cash flow | $3.15B | $2.48B | $2.91B | $2.32B | $2.92B | $4.96B | $2.89B | $2.43B | $2.47B | $2.07B |
| Free cash flow | $2.07B | $1.76B | $2.15B | $1.55B | $1.92B | $3.73B | $1.62B | $1.18B | $1.41B | $1.07B |
| Diluted shares | 291.2M | 293.4M | 293.4M | 293.2M | 292.9M | 294.1M | 302.7M | 307.2M | 307.3M | 306.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.88B | $1.23B | $1.55B | $1.35B | $1.68B | $1.32B |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $10.45B | $8.98B | $8.74B | $9.01B | $10.34B | $9.58B |
| Total assets | $36.37B | $34.93B | $37.51B | $37.87B | $38.90B | $38.56B |
| Total liabilities | $19.62B | $18.52B | $21.12B | $21.50B | $23.07B | $23.55B |
| Shareholders' equity | $16.76B | $16.41B | $16.39B | $16.36B | $15.82B | $15.00B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology